-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AzbgcJVZkktkWqR0I3Wx/PIhn9JmVZ7HbfXzuC+rKoJk0W1NotIBip6wLSi1Cmwy Kz8d/EMAFzowpmPk0yBQlw== 0000910680-02-000694.txt : 20020814 0000910680-02-000694.hdr.sgml : 20020814 20020814102751 ACCESSION NUMBER: 0000910680-02-000694 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20020814 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNE RESPONSE CORP CENTRAL INDEX KEY: 0000817785 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330255679 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-41038 FILM NUMBER: 02732135 BUSINESS ADDRESS: STREET 1: 5935 DARWIN COURT CITY: CARLSBAD STATE: CA ZIP: 92008 BUSINESS PHONE: 6194317080 MAIL ADDRESS: STREET 1: 5935 DARWIN COURT CITY: CARLSBAD STATE: CA ZIP: 92008 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: TRINITY MEDICAL GROUP INC CENTRAL INDEX KEY: 0001110557 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 880448027 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 3753 HOWARD HUGLES PARKWAY 2ND FLOOR CITY: LAS VEGAS STATE: NV ZIP: 89109 BUSINESS PHONE: 4152561995 MAIL ADDRESS: STREET 1: 3753 HOWARD HUGLES PARKWAY 2ND FLOOR CITY: LAS VEGAS STATE: NV ZIP: 89109 SC 13G 1 sc13g062602.txt SC 13G - 6/26/02 ----------------------------- OMB APPROVAL ----------------------------- OMB Number 3235-0145 Expires: October 31, 2002 Estimated average burden hours per response ..... 14.9 ----------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13D-102) UNDER THE SECURITIES EXCHANGE ACT OF 1934* INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13D-1(B), (C) AND (D) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(B) The Immune Response Corporation - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, par value $.0025 per share - -------------------------------------------------------------------------------- (Title of Class of Securities) 45252T10 ------------------------------------------------------------------------------ (CUSIP Number) June 26, 2002 ----------------------------------------------------------- (Date of Event which requires filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Statement is filed: [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 339099103 13G Page 2 of 5 Pages - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Trinity Medical Group USA, Inc. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Florida - -------------------------------------------------------------------------------- NUMBER OF SHARES 5 SOLE VOTING POWER BENEFICIALLY 2,000,000 OWNED BY ------------------------------------------------------------- EACH REPORTING 6 SHARED VOTING POWER PERSON 0 WITH ------------------------------------------------------------- 7 SOLE DISPOSITIVE POWER 2,000,000 ------------------------------------------------------------- 8 SHARED DISPOSITIVE POWER 0 - -------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,000,000 - -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.1% - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON* CO - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT CUSIP No. 339099103 13G Page 3 of 5 Pages - -------------------------------------------------------------------------------- ITEM 1. (a) Name of Issuer: The Immune Response Corporation (b) Address of Issuer's Principal Executive Offices: The Immune Response Corporation 5935 Darwin Court Carlsbad, CA 92008 ITEM 2. (a) Name of Person Filing: Trinity Medical Group USA, Inc. (b) Address of Principal Business Office or, if none, Residence: Trinity Medical Group USA, Inc. 30021 Tomas Street Suite 300 Rancho Santa Margarita, CA 92688 (c) Citizenship: Florida (d) Title of Class of Securities: Common Stock, par value $.0025 per share (e) CUSIP Number: 45252T10 CUSIP No. 339099103 13G Page 4 of 5 Pages - -------------------------------------------------------------------------------- ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.SS.240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A: Not applicable. ITEM 4. OWNERSHIP. The following is information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 2,00,000 shares. (b) Percent of class: 5.1% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 2,000,000. (ii) Shared power to vote or to direct the vote: None. (iii) Sole power to dispose or to direct the disposition of: 2,000,000. (iv) Shared power to dispose or to direct the disposition of: None. ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS Not applicable. ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON Not applicable. ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY Not applicable. ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP Not applicable. ITEM 9. NOTICE OF DISSOLUTION OF GROUP Not applicable. CUSIP No. 339099103 13G Page 3 of 5 Pages - -------------------------------------------------------------------------------- ITEM 10. CERTIFICATION Certification pursuant toss.240.13d-1(c): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. August 7, 2002 ---------------------------------------- Date TRINITY MEDICAL GROUP USA, INC. By: /s/ Gary E. Wilson ---------------------------------------- Signature Gary E. Wilson, Chief Financial Officer ---------------------------------------- Name/Title -----END PRIVACY-ENHANCED MESSAGE-----